Divalent metal transporter 1 (DMT1/SLC11A2) is associated with intracellular iron levels and iron homeostasis, and recent studies have shown that temozolomide, a first-line clinical agent for treatment of glioblastoma, can induce ferroptosis to inhibit cell growth by targeting DMT1 in glioblastoma [131]. Here, SLC11A2 is linked to glioblastoma.